Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 15,246

Document Document Title
WO/2024/038282A1
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, Y and B are as ...  
WO/2024/038068A1
The present invention relates to diazadibenzofuran derivatives and diazadibenzothiophene derivatives and to electronic devices containing these compounds, in particular organic electroluminescent devices containing these compounds in the...  
WO/2024/040190A1
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...  
WO/2024/037503A1
Provided herein are antibody-drug conjugates, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms o...  
WO/2024/037607A1
Provided are a class of PRMT5 inhibitor as represented by formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a solvate thereof. Further provided are a...  
WO/2024/039861A1
The present disclosure provides 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole derivatives of formula I as estrogen receptor modulators for the treatment of cancer.  
WO/2024/038029A1
The present invention relates to diazadibenzofuran derivatives and diazadibenzothiophene derivatives and to electronic devices containing said compounds, in particular organic electroluminescent devices containing said compounds in the f...  
WO/2024/037616A1
The present application relates to a compound containing cyclohexyl, in particular to a compound of formula (I-AA), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition c...  
WO/2024/032747A1
The present application relates to tricyclic compounds and medical use thereof. The structure is represented by formula (I). Specifically, the present application further relates to a preparation method for the compounds, a pharmaceutica...  
WO/2024/036176A1
Provided herein are heterocyclic compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. The subject compounds and compositions are useful for the treatment...  
WO/2024/036098A1
Provided herein are certain heteroaromatic macrocyclic ether compounds which are ROS1 and/or ALK inhibitors. These compounds or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, are sui...  
WO/2024/032799A1
The present disclosure relates to a preparation method of TTX or its analogues, and also relates to compounds useful for preparation method for TTX or its analogues.  
WO/2024/033667A1
The present invention relates to visible light sensitive photoremovable protecting groups and their parent compounds X including a xanthene, xanthenium or related cores, represented by formula (Xa): (Xa) wherein the substituents are as d...  
WO/2024/031089A1
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.  
WO/2023/235837A3
N-(2-(dimethylamino)ethyl)benzamide- or hydroxamic acid derivative-comprising compounds for the inhibition of certain kinases for use in certain kinase-mediated disease states. Pharmaceutical compositions, conjugates, and methods for tre...  
WO/2024/026536A1
The present disclosure relates to a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, prodrug or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compound. Th...  
WO/2024/031088A1
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...  
WO/2024/028519A1
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, Y and A are as defined herein. These compounds are photodynamic agents that generates reactive oxygen species when subjected to UV radiation. The invention also...  
WO/2024/031041A2
Disclosed is an oxygen-containing heterocyclic compound, and use thereof. The present disclosure provides an oxygen-containing heterocyclic compound represented by Formula I, a pharmaceutically acceptable salt thereof, deuterated derivat...  
WO/2024/022528A1
Disclosed are compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention provides a compound having a structure represented by general formu...  
WO/2024/025896A2
Provided are protein kinase C (PKC) theta inhibitor compounds. Also provided are methods of use of such compounds, as well as pharmaceutical compositions thereof.  
WO/2024/022372A1
The present disclosure relates to an antibody-drug conjugate and the use thereof. Specifically, provided is an antibody-drug conjugate as represented by formula I, or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptab...  
WO/2024/026323A1
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the ...  
WO/2024/022165A1
The present invention provides a series of structurally novel exatecan derivatives, pharmaceutically acceptable salts, stereoisomers or prodrugs thereof, and use thereof in the field of anti-tumor. The exatecan derivatives have a structu...  
WO/2024/026129A2
The invention provides novel tricyclic aryl compounds and derivatives thereof, and pharmaceutical compositions thereof and methods for treating diseases and disorders, such as various types of cancer.  
WO/2024/022244A1
The present application relates to a heterocyclic compound having biological activity represented by formula (I), a preparation method therefor and a pharmaceutical composition thereof, and further relates to an use of such a compound an...  
WO/2024/022167A1
The present invention provides a novel camptothecin derivative compound, a pharmaceutically acceptable salt, a stereoisomer, or a prodrug thereof, and a method for preparing same and use thereof. The compound has a structure represented ...  
WO/2024/022520A1
A toxin molecule suitable for an antibody-drug conjugate is provided. Specifically, a compound represented by the following formula (I), or a pharmaceutically acceptable salt or hydrate thereof is provided. The compound can be used to pr...  
WO/2024/026061A1
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject i...  
WO/2024/020734A1
Provided are methods for preparing camptothecin derivatives and their synthetic precursors.  
WO/2024/020380A1
Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...  
WO/2024/017380A1
Disclosed in the present invention are a tricyclic-containing macrocyclic compound and a use thereof, and particularly disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.  
WO/2024/020419A1
Substituted aza-quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspe...  
WO/2024/020536A1
Disclosed are topoisomerase inhibitor compounds as cytotoxic agents and further as payloads for antibody-drug conjugates. Also disclosed are methods of making and use of the compounds in the treatment of proliferative diseases.  
WO/2024/015346A1
Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for ce...  
WO/2024/014837A1
The present invention relates to: (a) an active camptothecin derivative represented by chemical formula 1, which is designed to bind to a DDX5 protein and E3 ligase; (b) a prodrug thereof designed to release the active camptothecin deriv...  
WO/2024/015229A1
Provided herein are compounds, conjugate products thereof, methods, and pharmaceutical compositions for use in treatment and diagnosis.  
WO/2024/012557A1
Provided herein are anti-apoptotic BCL-2 family protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or m...  
WO/2024/012523A1
A bioactive conjugate, and a preparation method therefor and the use thereof. Specifically, disclosed are an antibody-drug conjugate as represented by formula (XV), a preparation method therefor and the use thereof in the prevention and/...  
WO/2024/015497A1
This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...  
WO/2024/012308A1
A PRMT5 inhibitor, a preparation method therefor, and the pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical co...  
WO/2023/280638A9
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.  
WO/2024/012791A1
The present invention relates to an electrochemical process for the synthesis of pyrazolines and pyrazoles of formula (I). The process can be especially used for the synthesis of the herbicide safener mefenpyr-diethyl.  
WO/2024/012524A1
The present disclosure relates to a bioactive conjugate, and a preparation method therefor and the use thereof. Specifically, disclosed are an antibody-drug conjugate as represented by formula XV, and a preparation method therefor and th...  
WO/2024/015408A1
Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).  
WO/2024/015793A2
The present invention concerns a novel enantiomer of 9-(3-fluorophenyl)-5-(2- hydroxyethyl)-6,9-dihydro-[l,3]dioxolo[4,5-g]furo[3,4-b]quin olin-8(5H)-one (SU056), as well as pharmaceutically acceptable salts thereof, pharmaceutical compo...  
WO/2024/007851A1
A catalyst for amide synthesis and preparation and use thereof are disclosed. The catalyst is a thio or seleno pyranodipyrimidine compound and has a simple and novel structure, high catalytic efficiency, and good atom economy. The cataly...  
WO/2024/008044A1
A compound, which is a compound represented by formula (I) or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound represented by formula (I) can significantly i...  
WO/2024/008113A1
The present invention relates to a formamide-substituted heterotricyclic derivative represented by formula (I), a method for preparing same, and use thereof. The present invention further relates to a pharmaceutical composition comprisin...  
WO/2024/010782A1
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...  

Matches 1 - 50 out of 15,246